Knoa Pharma and GCAR Announce First Newly Diagnosed Glioblastoma Patient Randomized in Phase 2/3 GBM AGILE Evaluation of Tinostamustine and First Recurr…

Knoa Pharma LLC ("Knoa Pharma"), a public health-focused pharmaceutical company, and the Global Coalition for Adaptive ...
ascopubs.org

A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine

Prognostic role of VEGF, EGFR, COX-2, cERB-b2 and ER-alpha in stage 1 non-small cell lung cancers No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2007 ...

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress ...
ascopubs.org

Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

Neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy—Clinical trial in progress. This is an ASCO Meeting ...
STAT

Adaptive trial designs will increase clinical trial speed, safety, and effectiveness

Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...
USA Today

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of ...
National Academies of Sciences%2c Engineering%2c and Medicine

Public Engagement and Clinical Trials: New Models and Disruptive Technologies: Workshop Summary

“Our clinicians engage in research now. It’s the usual care of the patient, and we generate research information from it.” —Louis Fiore, VA Boston Healthcare System The workshop session on innovations ...
Nature

Moving toward response-adapted trials in oncology

The I-SPY clinical trial platform was designed to accelerate clinical development of neoadjuvant treatments for early-stage breast cancer. Although it is not without limitations, it provides a model ...
Nature

A multimodal deep learning approach for the prediction of cognitive decline and its effectiveness in clinical trials for Alzheimer’s disease

Alzheimer’s disease (AD) is an irreversible neurodegenerative disease that causes brain cells to degenerate, and its symptoms, such as memory impairment, greatly impact the activities of daily living ...
The New England Journal of Medicine

Prehospital Whole Blood in Traumatic Hemorrhage — A Randomized Controlled Trial

Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...
Nasdaq

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial ...
GeekWire

Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech

GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Taylor Soper on Jan 6, 2026 at 8:51 ...